Pharmacogenomics Testing Market - Historic Data (2019-2024), Global Trends 2025, Growth Forecasts 2037
Pharmacogenomics Testing Market in 2025 is evaluated at USD 14 billion. The global Market size was over USD 13.06 billion in 2024 and is anticipated to witness a CAGR of around 9%, crossing USD 40.04 billion revenue by 2037. North America is expected to garner USD 14.01 billion by 2037, attributed to increasing healthcare expenditure, the presence of manufacturers, and advancements in pharmacogenomics testing technologies.
The market for pharmacogenetic tests is driven by the growing body of information showing how genes affect pharmaceutical efficacy. Additionally, throughout the forecast period, the growing need for precision diagnosis and individualized medications is anticipated to support the growth of the market. New technology could be used by researchers in Boston and New York to cure or perhaps prevent diseases in ways that are not achievable with conventional medications. These researchers are striving to build genetic medicines.
The market expansion of pharmacogenetic tests is anticipated to be impacted by an increasing number of insurance companies' reimbursement policies for these tests. Over the course of the forecast period, rising healthcare spending and a greater uptake of cutting-edge products in developed and high-income nations are anticipated to boost the market for pharmacogenetic tests.
